Why the study?
Does dual antiplatelet therapy reduce ischemic events compared to aspirin alone in high-risk patients for secondary prevention?
Does dual antiplatelet therapy reduce ischemic events compared to aspirin alone in high-risk patients for secondary prevention?
Dual antiplatelet therapy with newer P2Y12 inhibitors reduces ischemic events but increases bleeding risk compared to aspirin alone in secondary prevention.
Cardiovascular and cerebrovascular events commonly arise from atherosclerotic plaque rupture that produces platelet activation, thrombus formation, and reduction of blood flow to the brain or heart. The inhibition of platelets with aspirin is effective in the secondary prevention of acute coronary events.1 The addition of clopidogrel (i.e., dual antiplatelet therapy), a platelet P2Y12-receptor antagonist, produces even greater secondary prevention of coronary events in high-risk patients for up to 1 year.2 Second-generation P2Y12 inhibitors (i.e., prasugrel and ticagrelor) produce further reductions in the risk of ischemic events over the same time frame, albeit with more bleeding complications.3, . . .
No takes yet. Share an insight, caveat, or question.
John F. Keaney (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: